CERS Q3 product revenue $39.8M, net loss $7.3M; FY product revenue guidance cut to $155-158M

Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2023. Recent highlights include: • Third quarter 2023 total revenue of $47.3 million was comprised of total product revenue of $39.8 million and government contract revenue of $7.5 million. • Completed Phase 3 ReCePI study enrollment in cardiovascular surgery patients, with top-line data readout on track for Q1 2024. • Attended first in-person AABB Annual Meeting since 2019, where presentations from transfusion medicine leaders highlighted the growing experience with the benefits of INTERCEPT-treated products, including INTERCEPT platelets and INTERCEPT Fibrinogen Complex (IFC). • Cash, cash equivalents, and short-term investments were $79.0 million at September 30, 2023. • Reaffirming commitment to achieve non-GAAP adjusted EBITDA breakeven in the fourth quarter of 2023. “We continued to make progress on multiple fronts in the third quarter,” said William “Obi” Greenman, Cerus’